Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Recordati Industria Chimica e Farmaceutica S.p.A. (REC.MI)
Milan, MI, IT
Recordati Industria Chimica e Farmaceutica S.p.A., together with its subsidiaries, researches, develops, produces, and sells pharmaceuticals in Italy, the United States, Spain, France, Germany, Russia, Ukraine, Turkey, Portugal, North Africa, and internationally. It operates through Specialty and Primary Care; and Rare Diseases segments. The company develops Maapliv for maple syrup urine disease; Isturia for endogenous Cushing’s syndrome; Cystadrops treatment of the ocular manifestations of cystinosis; Carbaglu for hyperammonemia due to n-acetyl glutamate synthase deficiency; Qarziba for neuroblastoma patients and patients with relapsed or refractory neuroblastoma; and Fotivda for renal cell carcinoma. It also develops Sylvant for idiopathic multicentric castleman diseases; Caphosol for oral mucositis; ENJAYMO for hemolysis in adults with cold agglutinin disease; Zanidip, Zanipress, Vazkepa, and Logimax for hypertension; Urorec and Avodart for symptoms of benign prostatic hyperplasia; and Livazo for dyslipidemia; Combodart/Duodart; Seloken for angina pectoris, myocardial infarction and cardiac rhythm disorders, as well as hypertension and functional heart disorders. In addition, the company offers Procto-Glyveno for internal and external hemorrhoids; Polydexa, Isofra, and Otofa for ear, nose and throat infections; Isturisa, for Cushing’s syndrome; Normosang, human hemin; Juxtapid, homozygous familial hypercholesterolemia;Ledaga, mycosis fungoides, T-cell cutaneous lymphoma;Tergynan, an anti-infective for gynecological infections; CitraFleet and Phosphosoda as bowel cleansers; Lomexin for gynecological and dermatological infections; Hexaspray, treatments for the oral cavity; Magnesio Supremo, a dietary supplement; Reaglia for schizophrenia; Eligard for hormone-dependent prostate cancer; and pasireotide in Phase II trial for patients with post-bariatric hypoglycemia, as well as other products. The company was founded in 1926 and is headquartered in Milan, Italy.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.58% | +2.79% | +2.18% | +8.79% | -1.44% | +6.67% | +0.10% | +14.44% | +14.52% | +112.72% | +21,247.15% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 3 | 0 |
| Buy | 4 | 0 |
| Hold | 5 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Medical - Pharmaceuticals: +7.8%+11.8% ★ Q1'26: +4.9% (vs Q1'25)
-
EPS growth Medical - Pharmaceuticals: +20.2%+6.5% Q1'26: +21.7% (vs Q1'25)
-
FCF margin FCF growth · Medical - Pharmaceuticals: +43.3%+15.9% Q1'26: +12.9% (vs Q1'25)
-
EBIT margin Medical - Pharmaceuticals: +6.8%+26.0% ★ Q1'26: +32.5% (vs Q1'25)
-
ROIC Medical - Pharmaceuticals: +6.1%+13.1% ★ Q1'26: +17.5% (vs Q1'25)
-
Share dilution Medical - Pharmaceuticals: +0.0%+0.0% Q1'26: +0.0% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Medical - Pharmaceuticals: 0.21×2.78× Q1'26: 2.08× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 10 Rev. Ana. 9 EPS Ana. |
Dec 2027 10 Rev. Ana. 8 EPS Ana. |
Dec 2028 8 Rev. Ana. 7 EPS Ana. |
Dec 2029 7 Rev. Ana. 2 EPS Ana. |
Dec 2030 7 Rev. Ana. 5 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
1.05B
est: 1.05B (0.0%)
|
1.15B
est: 1.15B (+0.0%)
|
1.29B
est: 1.29B (+0.0%)
|
1.35B
est: 1.35B (0.0%)
|
1.48B
est: 1.47B (+0.7%)
|
1.45B
est: 1.47B (-1.2%)
|
1.58B
est: 1.58B (+0.1%)
|
1.85B
est: 1.84B (+0.5%)
|
2.08B
est: 2.22B (-6.4%)
|
2.34B
est: 2.32B (+0.8%)
|
2.62B
est: 2.62B (-0.1%)
|
2.78B
2.76B – 2.82B
+6.2% YoY
|
3.01B
2.90B – 3.09B
+8.2% YoY
|
3.19B
3.17B – 3.20B
+5.8% YoY
|
3.52B
3.45B – 3.60B
+10.6% YoY
|
3.70B
3.62B – 3.78B
+4.9% YoY
|
| EBITDA |
321.76M
est: 364.35M (-11.7%)
|
377.71M
est: 401.29M (-5.9%)
|
456.66M
est: 447.96M (+1.9%)
|
501.50M
est: 470.39M (+6.6%)
|
537.15M
est: 511.91M (+4.9%)
|
566.83M
est: 510.03M (+11.1%)
|
578.35M
est: 548.73M (+5.4%)
|
559.35M
est: 641.60M (-12.8%)
|
708.16M
est: 750.00M (-5.6%)
|
795.37M
est: 783.23M (+1.6%)
|
887.00M
est: 883.86M (+0.4%)
|
938.73M
931.63M – 952.51M
+6.2% YoY
|
1.02B
979.36M – 1.04B
+8.2% YoY
|
1.07B
1.07B – 1.08B
+5.8% YoY
|
1.19B
1.16B – 1.21B
+10.6% YoY
|
1.25B
1.22B – 1.27B
+4.9% YoY
|
| EBIT |
283.27M
est: 294.34M (-3.8%)
|
339.78M
est: 324.18M (+4.8%)
|
408.51M
est: 361.88M (+12.9%)
|
440.22M
est: 380.01M (+15.8%)
|
459.12M
est: 413.55M (+11.0%)
|
473.16M
est: 412.03M (+14.8%)
|
480.77M
est: 443.30M (+8.5%)
|
433.59M
est: 518.32M (-16.3%)
|
565.49M
est: 595.09M (-5.0%)
|
628.35M
est: 621.46M (+1.1%)
|
680.56M
est: 701.31M (-3.0%)
|
744.84M
739.21M – 755.77M
+6.2% YoY
|
805.87M
777.09M – 827.62M
+8.2% YoY
|
852.90M
849.24M – 856.55M
+5.8% YoY
|
943.06M
922.13M – 962.94M
+10.6% YoY
|
989.62M
967.66M – 1.01B
+4.9% YoY
|
| Net Income |
198.79M
est: 200.77M (-1.0%)
|
237.41M
est: 239.10M (-0.7%)
|
288.76M
est: 293.84M (-1.7%)
|
312.38M
est: 315.07M (-0.9%)
|
368.83M
est: 335.73M (+9.9%)
|
354.98M
est: 381.40M (-6.9%)
|
385.97M
est: 411.17M (-6.1%)
|
312.34M
est: 432.43M (-27.8%)
|
389.21M
est: 387.01M (+0.6%)
|
416.51M
est: 555.49M (-25.0%)
|
443.62M
est: 639.09M (-30.6%)
|
653.29M
612.95M – 693.63M
+2.2% YoY
|
761.92M
733.97M – 789.87M
+16.6% YoY
|
733.88M
721.88M – 1.02B
-3.7% YoY
|
961.08M
933.35M – 987.42M
+31.0% YoY
|
1.01B
980.79M – 1.04B
+5.1% YoY
|
| SGA |
352.18M
est: 308.52M (+14.2%)
|
369.22M
est: 339.79M (+8.7%)
|
396.38M
est: 379.31M (+4.5%)
|
401.22M
est: 398.31M (+0.7%)
|
445.59M
est: 433.46M (+2.8%)
|
421.86M
est: 431.87M (-2.3%)
|
480.89M
est: 464.65M (+3.5%)
|
572.16M
est: 543.28M (+5.3%)
|
601.11M
est: 648.82M (-7.4%)
|
654.38M
est: 677.56M (-3.4%)
|
726.99M
est: 764.62M (-4.9%)
|
812.09M
805.95M – 824.00M
+6.2% YoY
|
878.62M
847.24M – 902.33M
+8.2% YoY
|
929.90M
925.91M – 933.88M
+5.8% YoY
|
1.03B
1.01B – 1.05B
+10.6% YoY
|
1.08B
1.06B – 1.10B
+4.9% YoY
|
| EPS |
0.97
est: 0.96 (+1.0%)
|
1.15
est: 1.14 (+0.6%)
|
1.40
est: 1.41 (-0.4%)
|
1.53
est: 1.51 (+1.5%)
|
1.80
est: 1.61 (+12.1%)
|
1.73
est: 1.82 (-5.2%)
|
1.87
est: 1.97 (-4.9%)
|
1.52
est: 2.06 (-26.4%)
|
1.89
est: 1.88 (+0.6%)
|
2.02
est: 2.66 (-24.0%)
|
2.16
est: 3.06 (-29.4%)
|
3.19
2.93 – 3.32
+4.4% YoY
|
3.68
3.51 – 3.78
+15.2% YoY
|
4.09
3.45 – 4.86
+11.1% YoY
|
4.60
4.46 – 4.72
+12.5% YoY
|
4.83
4.69 – 4.96
+5.1% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-11 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 1/5 | 2/5 | 2/5 |
| 2026-05-08 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 1/5 | 2/5 | 2/5 |
| 2026-05-07 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 1/5 | 2/5 | 2/5 |
| 2026-05-06 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 1/5 | 2/5 | 2/5 |
| 2026-05-05 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 1/5 | 3/5 | 2/5 |
| 2026-05-04 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 1/5 | 3/5 | 2/5 |
| 2026-04-30 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 1/5 | 3/5 | 2/5 |
| 2026-04-29 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 1/5 | 3/5 | 2/5 |
| 2026-04-28 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 1/5 | 3/5 | 2/5 |
| 2026-04-27 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 1/5 | 3/5 | 2/5 |
| 2026-04-24 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 1/5 | 3/5 | 2/5 |
| 2026-04-23 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 1/5 | 3/5 | 2/5 |
| 2026-04-22 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 1/5 | 3/5 | 2/5 |
| 2026-04-21 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 1/5 | 3/5 | 2/5 |
| 2026-04-20 | A | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 3/5 | 2/5 |
| 2026-04-17 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-04-16 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 2/5 | 2/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | State Street SPDR S&P Euro Dividend Aristocrats UCITS ETF (Dist) EUDV.L | 1.57% | 30.32M | 0.30% |
| 2 | UBS Factor MSCI EMU Low Volatility UCITS ETF EUR dis UD02.L | 1.30% | 132.6K | 0.25% |
| 3 | iShares MSCI Italy ETF EWI | 1.29% | 11.64M | 0.50% |
| 4 | TD Q International Low Volatility ETF TILV.TO | 1.23% | 1.14M | 0.40% |
| 5 | NYLI Merger Arbitrage ETF MNA | 1.06% | 2.68M | 0.75% |
| 6 | State Street SPDR EURO STOXX Low Volatility UCITS ETF (Acc) ZPRL.DE | 1.01% | 361.9K | 0.30% |
| 7 | Amundi Italy MIB ESG UCITS ETF Acc FMI.PA | 1.00% | 2.16M | 0.18% |
| 8 | Fidelity Europe Quality Income UCITS ETF ACC-GBP (hedged) FEQP.L | 0.88% | 750.2K | 0.35% |
| 9 | Fidelity Europe Quality Income UCITS ETF ACC-EUR FEQD.L | 0.88% | 639.8K | 0.30% |
| 10 | Fidelity Europe Quality Income UCITS ETF INC-EUR FEUI.L | 0.88% | 639.8K | 0.30% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Robert Koremans | Chief Executive Officer & Director | 2M | — |
| Alessandra Abate | Group Chief People & Culture Officer | — | female |
| Bibianne Bon | Group Chief Legal Officer | — | female |
| Cathrin Petty | Executive Director | — | female |
| Eugenia Litz | Vice President & Head of Investor Relations | — | female |
| Gabriele Finzi | Executive Vice President of Corporate Development, Licensing & Innovation | — | male |
| Giampiero Mazza | Executive Director | — | male |
| Laura Conti | Group Communications Director | — | female |
| Michael McClellan | Chief Financial Officer | — | male |
| Alberto Martinez | Executive Vice President of Specialty & Primary Care Business Unit | — | male |
| Scott Pescatore | Executive Vice President of Rare Diseases Business Unit | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for REC.MI
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
